New York, May 24, 2026, 18:04 (EDT)
- Virax closed Friday at 27.75 cents, down 9.31% on the day but still sharply above the prior Friday’s close.
- Shareholders are due to vote June 5 on a 10-for-1 to 30-for-1 reverse share consolidation.
- U.S. stock markets are closed Monday for Memorial Day; regular trading resumes Tuesday.
Virax Biolabs Group heads into the Memorial Day break with a Nasdaq listing fix in front of investors: a June 5 shareholder vote on a reverse share consolidation after another week of heavy, uneven trading in the micro-cap diagnostics stock. The plan would combine every 10 to 30 shares into one share, a move usually meant to lift the per-share price without changing an investor’s proportional stake.
The timing is tight. Virax said in its May 22 filing that Nasdaq gave it until July 11 to regain compliance with the exchange’s $1 minimum bid rule, meaning the shares must close at or above $1 for at least 10 straight business days. The company said that without shareholder approval, or without the stock otherwise meeting the rule, its ordinary shares could be delisted.
That makes the coming week awkward. There is no regular U.S. trading Monday because Nasdaq is closed for Memorial Day, leaving Tuesday as the next full session for investors to price the filing and the June vote. Nasdaq’s normal trading day runs from 9:30 a.m. to 4 p.m. Eastern time.
Virax finished Friday at $0.2775, down 9.31%, after trading between $0.2711 and $0.3421 on volume of 11.87 million shares. The stock was still up about 81% from its May 15 close of $0.1535, helped by a Monday surge of 53.09% and a Tuesday gain of 31.49%. The broader Nasdaq index rose 0.19% Friday, while the S&P 500 added 0.37%.
The buying burst was not tied to a same-day product approval or revenue release. A Schedule 13G/A, a disclosure used for certain large ownership stakes, showed Armistice Capital reporting shared voting and dispositive power over 1,000,239 Virax shares, or 4.99% of the class, in a filing signed May 15.
Virax is trying to shift investor attention back to ViraxImmune, its in-development T-cell immune-profiling platform for post-acute infection syndromes, or PAIS — lingering conditions after infections, including Long COVID and ME/CFS. In April, the company said its current U.S. market-entry focus was a laboratory-developed test, or LDT, a test designed and run through a specific laboratory, with broader in vitro diagnostic development to follow.
Chief Executive James Foster framed the next phase in plain execution terms. “Our task is to execute,” he said in the April shareholder letter. He also called the next stage “validation and preparation,” pointing to a planned PAIS data readout and U.S. market-entry work. Virax Biolabs Group Limited
Analyst coverage is thin. H.C. Wainwright cut its Virax price target to $1 from $3 in January while keeping a Buy rating, citing an expected increase in projected shares outstanding to 25.3 million over the following 12 months. The firm also noted that Virax had completed enrollment in a 160-subject UK study of ViraxImmune and expected initial data in the second quarter of 2026.
The listing issue puts Virax in the same capital-markets lane as other small diagnostics companies, even where products differ. Co-Diagnostics, a molecular diagnostics peer, said this week it planned a $3 million private placement priced at-the-market under Nasdaq rules; in March, it said it had regained Nasdaq compliance, including the $1 bid-price rule.
But a reverse split is not a clinical milestone and does not add cash. The downside case is simple: shareholders reject the measure, the stock fails to hold above $1 after any consolidation, or the coming PAIS data do not support the commercial path management has outlined. Virax itself warned that delisting could hurt liquidity, market price and access to capital.
For now, the tape matters almost as much as the lab work. Traders will watch Tuesday’s reopen, the volume behind any move, and whether the stock can hold Friday’s gains into the June 5 meeting rather than just print another brief spike.
